[1] Bray F,Laversanne M,Sung H,et al.Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin,2024,74(3):229-263.
[2] 中国抗癌协会肺癌专业委员会,中国胸部肿瘤研究协作组,中华医学会肿瘤学分会肺癌专家委员会.非小细胞肺癌围术期免疫治疗的共识与争议(2024 版) .中华肿瘤杂志,2024,46(12):1107-1126.
[3] Martins Rs,Razi Ss,Alnajar A,et al.Neoadjuvant vs adjuvant chemoimmunotherapy for stage II-IIIB non-small cell lung cancer.Ann Thorac Surg,2024,118(3):672-681.
[4] Vanguri RS,Luo J,Aukerman AT,et al.Multimodal integration of radiology,pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer.Nat Cancer,2022,3(10):1151-1164.
[5] Nelles C,Gräf M,Bernard P,et al.Real-world response assessment of immune checkpoint inhibition:comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients.Eur Radiol,2025,35(4):2084-2093.
[6] Cheng Y,Chen ZY,Huang JJ,et al.Efficacy evaluation of neoadjuvant immunotherapy plus chemotherapy for non-small-cell lung cancer:comparison of PET/CT with postoperative pathology.Eur Radiol,2023,33(10):6625-6635.
[7] 黄焰,张莉萍,侯立坤,等.非小细胞肺癌新辅助治疗后手术切除标本的病理评估.中华病理学杂志,2021,50(7):773-778.
[8] Chen ZY,Fu R,Tan XY,et al.Dynamic 18F-FDG PET/CT can predict the major pathological response to neoadjuvant immunotherapy in non-small cell lung cancer.Thorac Cancer,2022,13(17):2524-2531.
[9] Cascone T,Weissferdt A,Godoy M,et al.Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.Nat Commun,2021,12(1):5045.
[10] Karayama M,Yoshizawa N,Sugiyama M,et al.Intravoxel incoherent motion magnetic resonance imaging for predicting the long-term efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer.Lung Cancer,2020,143:47-54.
[11] Liu C,Zhao W,Xie J,et al.Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer.Front Immunol,2023,14:1115291.
[12] Ye G,Wu G,Zhang C,et al.CT-based quantification of intratumoral heterogeneity for predicting pathologic complete response to neoadjuvant immunochemotherapy in non-small cell lung cancer.Front Immunol,2024,15:1414954.
[13] Han X,Wang M,Zheng Y,et al.Delta-radiomics features for predicting the major pathological response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer.Eur Radiol,2024,34(4):2716-2726. |
京公网安备11010202007215号
ip访问总数: ip当日访问总数: 当前在线人数:
本作品遵循Creative Commons Attribution 3.0 License授权许可
